Opinion|Videos|November 20, 2026

Durable and Objective Sleep Outcomes in Menopause

Long-term patient-reported outcomes and dedicated objective sleep assessments offer complementary views of treatment response. The panel examines what OASIS-3 and NIRVANA add to the evolving evidence on VMS and sleep. Fifty-two-week data support durable improvement in VMS and sleep, while concordance across polysomnography, home monitoring, and sleep diaries strengthens confidence that benefits extend beyond patient perception.

"Durable and Objective Sleep Outcomes in Menopause" examines whether sleep benefits persist over a year and hold up under objective and consumer-device measurement. Durability and measurement quality are central to judging sleep benefits with neurokinin receptor antagonist therapy. The panel reviews long-term data showing that control of both vasomotor symptoms (VMS) and sleep was maintained over a full year of treatment. Dr. Pinkerton highlights the rapid onset of benefit as a practical advantage compared with hormone therapy.

Dr. Bertisch then discusses phase 2 data in women with objectively confirmed sleep disturbance, measured with polysomnography. The findings showed improvement in nighttime wakefulness, the hallmark of midlife sleep disruption. She cautions, however, that polysomnography offers only a brief snapshot and that insomnia remains a diagnosis rooted in what patients report. She views the objective findings as supportive of, rather than a replacement for, what women say about their sleep.

The conversation then turns to consumer wearables, which many patients now bring to appointments. Dr. Bertisch explains that these devices can reveal useful patterns over time but tend to overestimate sleep and can heighten anxiety about it. Dr. Hofmann notes that many patients become distressed by their data, so she focuses on how they feel they are sleeping.

The panel closes by considering how sleep diaries, home monitoring, and laboratory measures compare in the same participants. Dr. Bertisch explains that agreement across these different methods strengthens confidence that the treatment effect is real, while noting that larger studies are still needed. The episode helps clinicians interpret sleep outcome data more critically and understand the strengths and limits of each measurement approach used in research and in practice.

In "Residual Sleep Disruption and Breast Cancer in Menopause," the panel will weigh the SKYLIGHT sleep findings and consider care for breast cancer survivors on endocrine therapy.


Related to this article